Utilizing agonist mAbs to target select TNFR members has proven an effective treatment modality in preclinical cancer models [15–18], which has led to translational clinical studies of agonist mAbs specific for CD40, CD137, and OX40 [19–21]. Here, TNFRSF1A is linked to cancer.